Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3019% above fair value
$1.34−0.26 (-16.51%)
Close on Nov 12, 2026Market cap $160.56MP/E –Yield –
Fate Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Fate Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$119.66M. For fiscal 2025 it was -$134.80M. The highest annual figure on record is -$12.62M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$134.80M | – |
| FY2024 | Dec 31, 2024 | -$191.31M | – |
| FY2023 | Dec 31, 2023 | -$172.23M | – |
| FY2022 | Dec 31, 2022 | -$294.63M | – |
| FY2021 | Dec 31, 2021 | -$211.14M | – |
| FY2020 | Dec 31, 2020 | -$125.00M | – |
| FY2019 | Dec 31, 2019 | -$98.53M | – |
| FY2018 | Dec 31, 2018 | -$65.89M | – |
| FY2017 | Dec 31, 2017 | -$41.15M | – |
| FY2016 | Dec 31, 2016 | -$31.08M | – |
| FY2015 | Dec 31, 2015 | -$27.10M | – |
| FY2014 | Dec 31, 2014 | -$24.41M | – |
| FY2013 | Dec 31, 2013 | -$17.10M | – |
| FY2012 | Dec 31, 2012 | -$12.97M | – |
| FY2011 | Dec 31, 2011 | -$12.62M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$29.57M | – |
| Q2 FY2026 | Jun 30, 2026 | -$28.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$31.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$56.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$43.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$58.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$59.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$83.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$80.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$71.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$67.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$45.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$32.54M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.96M | – |
| Q1 FY2020 | Mar 31, 2020 | -$33.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.46M | – |
| Q3 FY2019 | Sep 30, 2019 | -$26.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.01M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.41M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.38M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.32M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.45M | – |
See a number that looks wrong?